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Abstract
Background: Although a grossly disproportionate burden of disease from HIV/AIDS, TB and
malaria remains in the Global South, these infectious diseases have finally risen to the top of the
international agenda in recent years. Ideal strategies for combating these diseases must balance the
advantages and disadvantages of 'vertical' disease control programs and 'horizontal' capacity-
building approaches.
Discussion: The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) represents an
important step forward in the struggle against these pathogens. While its goals are laudable,
significant barriers persist. Most significant is the pitiful lack of funds committed by world
governments, particularly those of the very G8 countries whose discussions gave rise to the Fund.
A drastic scaling up of resources is the first clear requirement for the GFATM to live up to the
international community's lofty intentions. A directly related issue is that of maintaining a strong
commitment to the treatment of the three diseases along with traditional prevention approaches,
with the ensuing debates over providing affordable access to medications in the face of the
pharmaceutical industry's vigorous protection of patent rights.
Summary: At this early point in the Fund's history, it remains to be seen how these issues will be
resolved at the programming level. Nevertheless, it is clear that significant structural changes are
required in such domains as global spending priorities, debt relief, trade policy, and corporate
responsibility. HIV/AIDS, tuberculosis and malaria are global problems borne of gross
socioeconomic inequality, and their solutions require correspondingly geopolitical solutions.
Background
World Health Organization (WHO) statistics estimate
that over 5.6 million people are killed by HIV/AIDS, tu-
berculosis and malaria every year, with virtually all of
these deaths occurring in the developing world [1]. This
virus, bacterium and parasite are the top infectious disease
killers in the world today. While the morbidity and mor-
tality stemming from the latter two agents have devastated
populations for centuries, the HIV/AIDS pandemic has
helped stimulate a recent surge of high-level interest in in-
fectious disease control launching all three diseases to the
forefront of public attention over just a few short years.
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Out of the growing momentum over these diseases has
emerged a potentially golden opportunity, in the form of
the new Global Fund to Fight AIDS, Tuberculosis and Ma-
laria (GFATM). Its creation demonstrates a significant step
forward, though important policy issues remain to be
worked out. What specific strategies will allow us to suc-
cessfully generate and maintain the global public good of
AIDS, tuberculosis and malaria control?
This paper will discuss the GFATM and important priori-
ties for the control of these diseases. An overview of the
policy context is presented first, discussing the reasons for
the recent surge of interest in these diseases and outlining
two general ways of conceptualizing disease control: 'ver-
tical', disease-specific control programs, and 'horizontal',
broader-based approaches. A brief analysis of the
GFATM's initial round of grants follows, examining its
balance between vertical and horizontal approaches, as
well as between treatment and prevention. Finally, the pa-
per describes the major obstacles to the GFATM's success
– namely, that of funding – and identifies specific political
and economic strategies for the international community
regarding the control of these diseases in the future.
Why All the Interest?
It has long been recognized that infectious diseases consti-
tute a significant global burden of disease. In 2001, HIV/
AIDS, tuberculosis and malaria together accounted for
11.4% of all disability-adjusted life-years (DALYs) global-
ly and 31.5% in Africa [1]. Based on these numbers alone,
the desire to combat these three diseases has been consid-
erable. But a variety of factors have increased this interest
still further. Not least among them is a shifting conceptu-
alization of infectious diseases which reclassifies them as
a threat to international security. The historical record
shows how uncontrolled infectious diseases have been
critical in the rise and fall of human societies, from the an-
nihilation of Native Americans to the fall of the Byzantine
Empire [2]. Present-day ecological changes such as the rise
of mega-cities, the ease of international transport, and the
destruction of the natural environment continue to in-
crease the infectious disease burden. Coupled with in-
creasing social inequalities, these global shifts may
overwhelm states' capacities for governance and econom-
ic growth, and exacerbate the threat of intra- or inter-state
conflict [3,4]. These dangers prompted the United Na-
tions Security Council to convene an unprecedented ses-
sion on the threat to Sub-Saharan Africa of HIV/AIDS in
January 2000, and prompted the Clinton administration
in the United States to appoint a National Science Council
on [the security threat posed by] Emerging and Re-Emerg-
ing Infectious Diseases. Clinton himself publicly declared
AIDS an international security threat at a World AIDS Day
commemoration in December 2000 [5].
Another motivation for high-level engagement around
AIDS, tuberculosis and malaria relates to domestic disease
control concerns. For instance, in most developed coun-
tries, tuberculosis is predominantly a disease of the for-
eign-born, albeit with a notable disease burden among
urban disenfranchised and other poor communities. In
such settings, it makes far more sense both economically
and in terms of public health to 'turn off the tap' of disease
burden by controlling tuberculosis at a global level than
to 'mop' the global tide of infectious disease through the
screening and management of individual patients [6].
There is increasing recognition of the need to broaden ho-
rizons beyond our borders and to acknowledge that glo-
bal forces and international policy shape the disease
patterns of our domestic populations.
Finally, a moral-rational model of 'global public goods'
has recently been advanced, which urges us to reconcieve
the benefits of infectious disease control in the developing
world as a common good with benefits for all humanity.
Global public goods are 'non-excludable' inputs to the
public domain which by definition are available for all to
enjoy. 'Enlightened self-interest' is one way of under-
standing of how one's own well-being is intrinsically tied
to that of one's neighbours, but for many, the gross health
inequalities between the industrialized and developing
world have become intolerable on purely ethical and
moral grounds [7].
Discussion
The Policy Context: Vertical Disease Control Programs vs. 
Horizontal Approaches
Traditionally, there are two general approaches to disease
control: 'vertical' disease-specific programs which are in-
dependent of the rest of the health care system, and 'hori-
zontal', broader-based approaches to improving health.
Vertical control programs are exemplified by the standard-
ized public health approach to TB. In the wake of skyrock-
eting TB rates around the world and the WHO's ensuing
declaration of TB as a "global public health emergency" in
1993, international authorities have rallied around a pub-
lic health package involving directly-observed therapy,
short-course (DOTS) as an absolute requirement for con-
trol of the disease [8,9]. DOTS has achieved good results
in numerous settings around the world [10,11].
A similar vertical approach to disease management has
been recently proposed for HIV/AIDS as well, calling for
centralized, national programs for the delivery of antiret-
rovirals in the developing world, either alongside or di-
rectly integrated with existing TB programs [12]. The
strength of such vertical mechanisms is in the attention
paid to all aspects of disease control, spanning the contin-
uum from prevention to treatment and follow-up, and
from government commitment to standardized clinicalBMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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care. Indeed, the text of the recent United Nations General
Assembly Special Session (UNGASS) Declaration of Com-
mitment on HIV/AIDS addresses a wide array of HIV-re-
lated imperatives ranging from clinical prevention and
treatment to human rights, from socioeconomic impact to
research and development [13]. The fierce commitment of
such programs' proponents offers inspiration and hope to
those who refuse to 'write off' the health challenges of the
developing world as unsustainably expensive or not 'cost
effective'.
Vertical programs are not without their critics, however.
Often, they are seen as focussing too exclusively on one
health problem while unjustly ignoring others. In invest-
ing solely in one disease, they may fail to build local ca-
pacities to foster broader health benefits. In particular,
DOTS vertical programming has received a wealth of crit-
icism, though generally for reasons specific to TB-DOTS
programs. For instance, observers of operational research
on DOTS have commented that there is a lack of standard-
ization regarding the exact program inputs in studies re-
porting on DOTS program successes [14]. Foucauldian
critiques consider the program's fixation on 'supervised
swallowing' to be dehumanizing and authoritarian [15].
Of great practical consideration, there is widespread con-
cern that DOTS may simply not be attainable in resource-
poor settings. In fact, two randomized controlled trials
comparing DOTS with self-supervision, family supervi-
sion, or both, failed to demonstrate the superiority of di-
rect observation by a health worker, suggesting that
cheaper and more convenient forms of treatment supervi-
sion than DOTS merit consideration. The first trial, con-
ducted in South Africa, reported greater treatment success
among self-supervised patients (60%) than DOTS pa-
tients (54%) [15]. The second, conducted in Pakistan, re-
vealed similar results for all forms of direct observation:
64% cure rates for DOTS, 55% for family supervision, and
62% for self-supervision [16]. Suggestions that downplay
the supervisory role of health care professional have thus
emerged, arguing that the counselling and personal sup-
port capacities of treatment observers are more important
factors in the program's success [17,18].
More complex analyses of tuberculosis control point to
the insidious emergence of multi-drug resistant tuberculo-
sis (MDRTB) as both evidence and predictor of DOTS'
shortcomings. MDRTB refers to strains of the bacterium
which are resistant to at least isoniazid and rifampin, the
two drugs at the foundation of standard DOTS therapy
(though strains may be resistant to other drugs as well).
Mathematical modeling [19], medical anthropological
studies [20], and epidemiological surveys in at least 6
countries [21] demonstrate how the formulaic applica-
tion of DOTS in the era of multidrug resistance can fuel a
growing epidemic of MDRTB. The failure of vertical pro-
gramming, it is argued, lies in the inadequacy of underly-
ing health care systems and, more fundamentally, in the
virulence of a globalizing world system which marginaliz-
es the poor [22,23]. Despite its virtues, broader approach-
es are clearly needed which address the complex ways in
which poverty and inadequate access breed resistance.
An alternative framework for addressing these systemic
forces is a 'horizontal' approach to public health, in which
emphasis is placed on basic needs and essential health in-
frastructure. Indeed, it is widely pointed out that through-
out the world, 95% of people living with HIV/AIDS lack
access to basic health care services [24]. Since 1978, one
popular way of conceiving this approach is through the
promotion of Primary Health Care, the focus of an oft-cit-
ed WHO International Conference in Alma-Ata, USSR, in
that year [25]. The Declaration of Alma-Ata advocates a
multifactorial approach involving health education, an
adequate food supply, nutrition, safe water and sanita-
tion, maternal and child health, immunization, disease
control and prevention, and the provision of essential
drugs.
More recently, the international development community
has promoted another horizontal approach to known as a
'Sector Investment Program' or, when applied to the
health domain, a 'Sector-Wide Approach' (SWAp). This
technique, first proposed by the World Bank in 1995 and
pioneered in several countries in Sub-Saharan Africa and
South Asia, represents a novel approach to 'development'
and 'aid' which builds on the well-described failures of
project-oriented funding and structural adjustment pro-
gram approaches [26–28].
SWAps involve a series of crucial steps that differentiate
them from previous models. First, agreement is reached in
advance among local government, donors, and locally ac-
tive non-governmental organizations (NGOs) on a clear
set of priorities within a given sector (e.g., the health sec-
tor). Donor monies are then pooled into a transparently-
monitored, locally-controlled fund, which is used to fi-
nance sector activities in order of pre-specified priority. A
SWAp thereby does away with the fragmentation and in-
efficiency of project-by-project, donor-by-donor ap-
proaches, in favour of a coherent, mutually-agreed upon
policy framework which is under local, rather than donor,
control. Poverty reduction and the rational prioritization
of development initiatives are key components of the
strategy, making it a potentially effective mechanism for
addressing horizontal public health goals. Present experi-
ence with SWAps has been limited to only a few African
and Asian countries, and tensions remain over the chang-
es demanded of funding agencies (e.g., financing of recur-
rent rather than one-time expenditures), the balance
between government and NGO priorities, and other keyBMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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areas [28]. Nevertheless, results have been encouraging
thus far, and their potential to broadly address the health
problems of the global South remains significant.
But horizontal approaches, too, have their limitations.
Since the Alma-Ata commitment to 'Health for All by the
year 2000' was announced, for instance, HIV/AIDS has
emerged and flourished, while the continuing death tolls
of malaria and tuberculosis rates seem to demand specific
attention. There is also widespread concern that vertical,
disease-specific programs – notwithstanding their own in-
adequacies – will not fit into SWAp frameworks at all. In-
deed, a recent report from Zambia describes how SWAp
policy reform in that country led to the collapse of its pre-
viously effective tuberculosis program [29].
The challenge ahead for the control of HIV, tuberculosis
and malaria will be in achieving an appropriate balance
between targeted interventions for these major killers and
broader programs targeting the underlying inadequacies
which predispose people to poor health. As argued recent-
ly in the Bulletin of the World Health Organization,
The two approaches are not in opposition to each other
and a false choice between vertical and horizontal ap-
proaches should not threaten international cooperation
for disease control, nor should disease control be promot-
ed at the cost of health sector development or of focusing
on non-communicable diseases . . . To accomplish target-
ed health-policy outcomes, the international community
should therefore encourage organizations such as WHO
to complement horizontal, health sector programmes
with vertical multisector, multilevel initiatives [7].
Disease-specific interventions could, for instance, be used
as a springboard for investments into the health care sys-
tems which buttress them. In the realm of HIV control, for
instance, targeted efforts to decrease mother-to-child HIV
transmission via AZT/nevirapine prophylaxis should be
conceived not as stand-alone interventions, but rather as
integral parts of a maternal and child health care package
[30]. Such an integrated approach would ideally include
disease-specific interventions such as antiretroviral thera-
py for the mother, voluntary counseling testing for her
sexual/blood contacts, as well as psychosocial support. At
the same time, it would strengthen health infrastructure
through pre- and postnatal care, STD counseling and
screening, nutritional supplementation and family plan-
ning.
In fact, experience with integrating HIV- and tuberculosis-
specific interventions into broader community health
programs has already been reported from the developing
world. Through its 'HIV Equity Initiative' in rural Haiti,
one group has employed community health workers, so-
cial and economic support for families, and simplified
clinical treatment algorithms to integrate vertical HIV
prophylaxis and highly-active antiretroviral therapy
(HAART) into an existing community clinic [31].
The same group has also advocated a newer vertical ap-
proach to MDRTB known as DOTS – Plus, a standard
DOTS protocol enhanced by individually-tailored phar-
macotherapy [32]. While critics may contend that this is
too costly and technically demanding for a resource-poor
setting, its advocates contend that the treatment of
MDRTB is the only rational and morally acceptable med-
ical and public health response to this phenomenon. They
and others have demonstrated its feasibility in rural Haiti,
the slums of Peru and urban Turkey [20,33,34], and have
successfully integrated the program into a community-
based health care setting which addresses patients' broad-
er health needs. Further, to bolster this aggressive ap-
proach, encouraging progress has been made in
negotiating price reductions for second line anti-tubercu-
lous drugs through a WHO-convened Working Group and
its 'Green Light Committee' [35].
Clearly, vertical disease control programs must be com-
plemented by broader, horizontal approaches to health
care and health infrastructure if AIDS, tuberculosis and
malaria are to be controlled. By extension, policy makers
must consider the broader socioeconomic inputs to
health if outcomes are to be improved – an approach
which may require higher-level political commitments
and systemic, structural change.
The Global Fund: A Golden Opportunity?
The GFATM is an international financing initiative repre-
senting the new-found determination of the international
community to address the health impact of the three dis-
eases. The Fund was born out of discussions at the
Okinawa G8 Summit in July 2000, and was made con-
crete by UN Secretary General Kofi Annan's call to action
in April 2001. Bolstered by the subsequent United Na-
tions General Assembly Special Session on HIV/AIDS
(UNGASS) in June 2001, and by the G8 Summit in
Genoa, July 2001, the Fund has become operational in a
remarkably short period of time. After a rigorous selection
process, the Fund announced its first round of grants in
April 2002 [36], through which $616 million will be dis-
persed over two years [37].
Two issues are of particular interest in this granting proc-
ess. The first relates to how the Fund tackled the question
of balancing vertical, disease-specific 'product support'
against horizontal health systems support. Though its
name suggests a distinctly vertical approach, the Fund's
stated intentions are to "address the three diseases in ways
that will contribute to strengthening health systems". ItBMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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aims to support proposals which "build on, complement
and coordinate with existing . . . national policies, priori-
ties and partnerships, including Poverty Reduction Strate-
gies and sector-wide approaches" [36]. On paper, its list of
approved projects from the April 2002 round of grants ap-
pears to have favoured disease-specific programming, in-
cluding comprehensive 'prevention and control'
strategies, the social marketing of disease prevention,
DOTS expansion programs, and a few cases of product
support (eg. bednets in Tanzania, antiretrovirals in Niger-
ia) [36].
One strategy the Fund has employed to ensure a broad
consensus on an individual country's programming is to
require that every application be done through a partner-
ship that includes representatives from governments, civil
society, and people affected by the diseases. The goal of
these Country Coordinating Mechanisms (CCMs) is to
improve coordination of their activities and to avoid du-
plication [36]. But the extent to which the GFATM lives
true to its goal of building broad-based health systems
thus remains to be seen.
The Global Alliance for Vaccines and Immunizations, an-
other global body active in the arena of international
health, appears to provide a model for balancing these ap-
proaches:
The alliance's executive director is reported to have said
that an optimum balance might be 60% of funds for new
vaccines and 40% for strengthening immunization servic-
es. To encourage recipients to meet the targets set, addi-
tional funds for strengthening health systems will be
released only once the countries have reached higher lev-
els of immunization coverage [38].
But ironically, "failure to meet targets could indicate the
need for greater support to weak health systems rather
than withholding of funds" [38].
Investing in horizontal programs for developing health
systems would not only provide much-needed basic serv-
ices for individuals suffering from these and other diseases
at present, but would also lay essential groundwork for
the future delivery of targeted interventions such as medi-
cations and immunizations, once they become available.
The way ahead lies in fostering innovative solutions that
integrate vertical, disease-specific programming for AIDS,
tuberculosis and malaria with much-needed health sys-
tems support.
The second issue of interest in the Fund's granting process
was how the Fund balanced treatment programs with pre-
vention programs in allocating its monies. It is now wide-
ly recognized that antiretroviral treatment is a cornerstone
of HIV/AIDS control that must not play second fiddle to
prevention, and that treatment for HIV plays an important
role in controlling tuberculosis and malaria infection as
well [39]. In its official call for funding applications in
January, the GFATM articulated a commitment to the
"prevention, treatment, care and support of the infected
and directly affected" [36], and in his July 2002 speech to
the XIV International AIDS Conference in Barcelona, exec-
utive director Richard Feachem reiterated this dedication.
He stated that the first round of grants "will double the
current number of people receiving Highly Active Anti-
Retroviral Therapy (HAART) in the developing world and
in Africa HAART recipients will increase six fold as a result
of these commitments" [40].
But as Feachem himself acknowledges, these achieve-
ments are "nothing like enough". The inadequacy may
largely be due to the continual reluctance of industrialized
countries to finance treatment programs – particularly for
expensive antiretroviral (ARV) therapy. Indeed, officials
from Malawi and other countries were allegedly encour-
aged by donor countries to remove a treatment compo-
nent from their GFATM proposal [37]. Yet at around the
same time, the WHO made the groundbreaking move of
adding ARVs to its Essential Medicines List [41].
The debate over funding medicines encompasses a deeper
issue, about balancing the potentially limitless need for
costly pharmaceuticals with the financial interests of the
pharmaceutical companies that manufacture them. Macr-
oeconomic analysis by the United Kingdom's Perform-
ance and Innovation Unit (UKPIU) [24] asserts that in
order to establish any reasonable hope for the widespread
availability of medications, vaccines and other health
products for these diseases in the future, the Fund should
provide a secure market for affordably-priced goods. Fur-
ther, it should signal this commitment through advance-
purchase commitments. The document argues that it is
only through a willingness to cover the costs of manufac-
ture, as well as the financial risks of research, that the glo-
bal community can hope to drive research and
development into essential medicines and vaccines.
But wherein lies the balance of power in a system which
lays corporate bottom lines at the foundation of a global
effort to combat the diseases of poverty? Half the mem-
bers of the commission that wrote the UKPIU report are
from the pharmaceutical industry. By no means does this
invalidate their findings – indeed, the report applies
sound economic theory in reaching rational, pragmatic
conclusions. But already, the public sector provides most
of the market for pharmaceutical products, through pub-
lic health insurance schemes. Furthermore, a review of the
chemotherapeutic agents developed by the pharmaceuti-
cal industry over the past 25 years reveals how despite in-BMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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creased protection in the form of extended patent
durations, the industry has not shown a concomitant in-
crease in innovation [42]. The lack of new medicines for
neglected diseases of the world's poor populations is pal-
pable: of 1393 new chemical entities marketed over this
time period, only 16 were for tropical diseases and tuber-
culosis [42]. Taken together, these arguments form the ba-
sis for calls for innovative new mechanisms for improving
the development of and access to therapies for major in-
fectious diseases.
Contrasting the views of industry are the recommenda-
tions of another global constituency with vested interests
in the GFATM's design – namely, the health NGO sector.
Deeply concerned about the Fund becoming a mere 'phar-
maceutical industry subsidy' [43], NGOs have made pas-
sionate pleas that priority be given to finding the most
affordable, effective treatment available when GFATM
monies are used to purchase medications. As observed by
Director of Médecins Sans Frontières' Access to Essential
Medicines Campaign Bernard Pecoul, an explicit state-
ment of this commitment is conspicuously missing from
the Fund's official documentation [44].
Practically speaking, the Fund must ensure that expensive,
brand-name antiretroviral drugs are not blindly pur-
chased where legal mechanisms could allow the purchase
of up to three times the quantity of an equally efficacious
generic version of the same medications. In the excite-
ment over ensuring that large-scale efforts to treat the
three diseases maintain adequate respect for intellectual
property rights, potential beneficiaries must be explicitly
reminded that obtaining generic and branded medicines
through alternative mechanisms such as compulsory li-
censing and parallel import arrangements are entirely
consistent with the Trade-Related Aspects of Intellectual
Property Rights agreement (TRIPS) [45]. The legality of
these measures was explicitly agreed to at the WTO's 2001
meeting in Doha, Qatar. Paragraph four of the declaration
reads: "We agree that the TRIPS Agreement does not and
should not prevent Members from taking measures to
protect public health. Accordingly, while reiterating our
commitments to the TRIPS Agreement, we affirm that the
Agreement can and should be interpreted and implement-
ed in a manner supportive of WTO Members' right to pro-
tect public health and, in particular, to promote access to
medicines for all" [46]. Practical legal experience such as
that garnered through Brazil's success with using the
mechanism of compulsory licensing to reduce the price of
both generic and brand ARVs down should be translated
elsewhere, so that potential applicants might gain access
to the most affordable quality medicines.
Of relevance to this discussion of pharmaceutical and
NGO interests, another set of policy tensions in the
GFATM's history relates to its governance. The very com-
position of the Fund's Executive Board was under conten-
tious debate in preliminary sectoral consultations by the
Fund's Transitional Working Group. Since its inception,
the Fund has billed itself as a "public-private partnership",
yet consultation with the NGO sector initially recom-
mended that no representatives of the pharmaceutical in-
dustry be members of the Board. Meanwhile, the private
sector itself asked for more than the proposed two allotted
positions on the Fund's 15-person Board, requesting in
the interim an additional ex-officio observer seat. For the
present, both constituencies retain two Board positions,
which will hopefully preserve a balance between private
and public perspectives.
The Challenge of Funding the Fund
The Global Fund represents an important opportunity for
visionary leadership and meaningful action towards re-
ducing the horrific tolls of HIV/AIDS, TB and malaria. The
challenges which lie ahead for the GFATM lie in fostering
and funding innovative projects which integrate vertical
approaches with horizontal approaches, and balance pre-
ventive programs with treatment. But even beyond these
programming dilemmas, how easily will it reach its lofty
goals?
A quick survey of the GFATM's progress to date reveals its
first major barrier, in the form of grossly inadequate
funds. If the international community is truly as commit-
ted to stamping out these three diseases as it would have
the world believe, it must drastically scale up its financial
commitments. At this writing, the fund totals little more
than $2.1 billion [36] – a relatively paltry sum when com-
pared to a recent report that put the minimum price tag
for global HIV control at $7.5 billion annually for that dis-
ease alone [47]. Commendable shows of leadership have
been made by Kofi Annan himself, who initiated the fund
by personally donating $100,000 of prize money from his
Philadelphia Liberty Medal, and by the governments of
Sub-Saharan Africa, which set target commitments of 15%
of their annual national budgets to be devoted to health
sector improvements for HIV/AIDS at an April 2001 sum-
mit in Abuja, Nigeria. But what of the leadership from the
G8 countries, out of whose own summits the very idea of
the Global Fund first arose?
To date, the G8 have collectively committed about $1.6
billion of the $2.1 billion total [36]. The Unites States has
pledged by far the greatest proportion of this amount, at
$500 million. But these seemingly impressive dollar fig-
ures fall far sufficient of the money needed. At least $US
1.3 billion each year is required to support basic com-
modities for prevention and treatment for malaria among
vulnerable groups [48]. Thus far, less that $US 23 million
has been awarded by the Fund for Malaria. African coun-BMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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tries, which represent 90% of the global malaria burden,
gets only $US 12.7 million [48]. In the wake of post-Sep-
tember 11 anthrax scares, for instance, the 2003 US
Homeland Security Budget has proposed $5.9 billion to
defend against bioterrorism [49]. Similarly, the seemingly
astronomical price tag of $7–10 billion for HIV/AIDS con-
trol is dwarfed by the still more astronomical annual ex-
penditures on military and defense budgets the world
over. Global military spending totaled $1 trillion in 1990
alone, and industrialized countries spend 5.3% of GNP
on military expenditures each year [23]. In contrast, these
same countries spend less than 0.3% of GNP on overseas
development assistance (ODA) each year – far short of
their mutually-agreed upon target of 0.7–1.0% of GNP
[23].
A glimmer of hope shone over the weeks leading up to the
recent June 2002 G8 Summit in Kananaskis, Canada,
where a 'New Partnership for African Development'
(NEPAD) was placed high on the agenda. Drafted by Afri-
can leaders themselves, the proposal's great innovation
was that aid spending on the continent would be more re-
liably spent, since NEPAD required them to pass an Afri-
can peer review process. But despite the enthusiasm about
this attention to Africa, the industrialized countries still
failed to make AIDS, tuberculosis and malaria a priority in
Kananaskis. UN Envoy on AIDS in Africa Stephen Lewis
made this point abundantly clear in his speech to the Al-
ternative Summit that ran parallel to the official G8 pro-
ceedings [50]. He notes that while the NEPAD document
sets admirable goals (an annual growth rate of 7% for fif-
teen years, halving poverty by 2015, a two-thirds reduc-
tion in infant mortality, a 25% reduction in maternal
mortality, and education for all children), none of them
are realistically attainable unless the HIV/AIDS pandemic
receives the attention it deserves. Yet, NEPAD pays little
attention to the disease in its proposals.
The global community must rethink its approach to 'de-
velopment', with HIV/AIDS and the other major infec-
tious diseases at the core of its analysis. This is precisely
the argument of the much-heralded recent WHO Report
of the Commission on Macroeconomics and Health. In it,
Jeffrey Sachs asserts that
The burden of disease in some low-income regions, espe-
cially sub-Saharan Africa, stands as a stark barrier to eco-
nomic growth and therefore must be addressed frontally
and centrally in any comprehensive development strategy.
The AIDS pandemic represents a unique challenge of un-
precedented urgency and intensity. This single epidemic
can undermine Africa's development over the next gener-
ation, and may cause tens of millions of deaths in India,
China, and other developing countries unless addressed
by greatly increased efforts [51].
The importance, then, of combatting AIDS, tuberculosis
and malaria has been made clear in the global arena. If
global health is truly understood as a 'global public good',
the necessary finances must be mobilized by whatever
means necessary.
One proposal offers compelling reasons to open up na-
tional health budgets to fund health development in the
international arena [7]. By this argument, money budget-
ed for investment in the health of one country's popula-
tion is just as appropriately spent on global health
problems as domestic ones, since the health of the world's
populations are so closely intertwined. Regardless of the
accounting logistics, it must ultimately be realized that the
funds required for the control of AIDS, tuberculosis and
malaria do exist, and must be made available through a
careful re-examination of funding priorities.
The Way Ahead
The GFATM holds considerable promise for harnessing
true international commitment to addressing the three
diseases. But even if the Global Fund attains its massive
targets of $7–10 billion US per year, does it truly have the
capacity to mend the damage from diseases so mired in
centuries of growing global inequality?
HIV/AIDS, tuberculosis and malaria are diseases that de-
mand consideration of populations' underlying predispo-
sition to disease in the forms of socioeconomic inequality
and abject poverty. While the motivations of the interna-
tional community for addressing the diseases include
pragmatic concerns of international security, economic
prosperity and domestic health status, they must ultimate-
ly include the ethical responsibility to redress gross ine-
qualities. Adequate attention to the systemic forces
underlying these infections thus necessitates correspond-
ingly systemic solutions.
As discussed already, not least among these is the need to
mobilize far larger sums of money to invest in world
health and in redressing social inequalities. For decades,
much of Africa has been left to stagnate in a perpetual
"poverty trap" [52], in which the state is simply too poor
to provide adequate basic living conditions for the popu-
lation. Infectious diseases are both a cause and a conse-
quence of this lack of health care, education and
infrastructure. Direct financial transfers and investment in
basic needs in such countries are the only viable solutions
to the continent's ongoing health and economic crises.
Hand in hand with this financial commitment is the need
to relieve those developing countries with unreasonable
debt burdens of these outlandish costs. Debt repayment
schedules paralyze national budgets and lock them into
paying back unsustainable sums of money to high-in-BMC International Health and Human Rights 2003, 3 http://www.biomedcentral.com/1472-698X/3/2
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come countries and financial institutions every year. On
average, debtor countries pay one and a half times as
much in servicing debt as they do on health care [53].
Debt relief is imperative if the Global South's bankrupt
governments are ever to address their populations' basic
health needs. Economic theory asserts that for a creditor
nation, "the outright cancellation of debt becomes . . . a
necessary part of its foreign policy" if it hopes to promote
economic growth as well as its own strategic interests in
bankrupt states [47,52].
Similarly, industrialized countries must reform trade pol-
icies that create absurd financial barriers to the integration
of poor countries' economies into the global marketplace.
Import tariffs on many African goods destined for the
United States, for examples, can reach levels of up to 33%
– up to 15 times the average US tariff rate of 2% [54].
Structural barriers such as these clearly impair the capacity
of poor countries to attain anything close to equal footing
with rich ones in their attempt to bring economic prosper-
ity to their people.
Finally, in our increasingly globalized economic system,
the 'right' of transnational corporations to global patent
protection for medicines that are almost exclusively sold
to the minority in the rich West must become more inti-
mately tied to their international responsibilities, in the
form of technology transfer, local capacity building, and
investments in basic infrastructure. Nowhere is this more
true than for the pharmaceutical industry, where the pub-
lic sector must play an active role in obliging its private
sector partners to invest in research and development for
neglected diseases, commit to equitable pricing schemes
and participate in technology transfer. It is only by linking
rights and responsibilities that we can hope to achieve im-
proved health for all the world's inhabitants.
Summary
Research abounds which links these glaring inequalities
and potential solutions to epidemic infectious diseases.
The UNGASS Declaration of Commitment on HIV/AIDS
already represents one forum in which the global call for
such measures as ODA increases and debt relief has been
clearly spelled out [13], and the Commission on Macr-
oeconomics and Health has provided another powerful
voice for increased international commitment. The chal-
lenge ahead lies in directly transforming research data and
our moral obligation into concrete international policy.
HIV/AIDS, TB and malaria are diseases mired in long-
standing fundamental inequalities. Structural changes in
policy such as a realignment of spending priorities, debt
relief, equitable trade policies and a commitment to glo-
bal corporate responsibility must complement other eco-
nomic aid mechanisms for improving public health in the
future. Achieving an appropriate balance between vertical
and horizontal programming and between prevention
and treatment strategies are issues to be resolved by the
GFATM and other institutions at the programming level.
At a more fundamental level, the G8 countries that spear-
headed the GFATM initiative must show political and fi-
nancial leadership in putting these cold, sobering realities
at the forefront of the international agenda if their inten-
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